The Latest Cardiac and Vascular News
FDA Advisory Committee to Review the New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nasdaq has halted the trading of the Company’s common stock. The […]
Correlations between lifestyle changes and blood pressure indicate how a person could increase their walking to positively impact heart health MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced new data on how minor lifestyle and behavioral changes can have a significant […]
MARLBOROUGH, Mass., Dec. 11, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited (“Acotec” and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company that offers solutions […]
Biomaterial catheters help avoid common vascular access complications, delivering improved patient outcomes and a lower cost of care BILLERICA, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI) today announced that Riverside Medical Center, located just outside the Chicago area, was the first in the nation to use its […]
McDermott + Bull Partner Ken Dropiewski talks with Endeavour Vision Partner Rob Barmann about what his team looks for in prospective partners in new venture opportunities.
CHICAGO, Dec. 8, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint […]
– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis – […]
NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on February 1, 2023 to stockholders of record at the close of […]
Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer1 TITUSVILLE, N.J., Dec. 9, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing […]
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards’ chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company’s Annual Meeting […]
